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Effects of continuous positive airway pressure on systemic
inflammation in patients with moderate to severe obstructive
sleep apnoea: a randomised controlled trial
Abstract
BACKGROUND: Obstructive sleep apnoea syndrome (OSAS) has been associated with cardiovascular
disease in epidemiological and observational studies. Continuous positive airway pressure (CPAP) is the
treatment of choice for OSAS, but the impact of this intervention on systemic inflammation involved in
the atherosclerotic process remains unclear. METHODS: 100 men with moderate-severe OSAS were
randomised to therapeutic (n = 51) or subtherapeutic (n = 49) CPAP treatment for 4 weeks to investigate
the effects of active treatment on inflammatory markers such as highly sensitive C reactive protein
(hsCRP), interleukin (IL)6, interferon gamma (IFNgamma) and anti-inflammatory adiponectin.
RESULTS: 4 weeks of therapeutic CPAP did not significantly change blood levels of hsCRP compared
with the subtherapeutic control group (difference between median changes -0.24 mg/l (95% CI -0.88 to
+0.24); p = 0.30). Plasma levels of IL6 and IFNgamma did not change significantly following
therapeutic compared with subtherapeutic CPAP (difference between median changes +0.52 and -0.07
pg/ml (95% CI -0.72 to +1.94 and -0.81 to +0.44); p = 0.45 and p = 0.82, respectively). Furthermore, 4
weeks of therapeutic CPAP did not significantly change levels of adiponectin in plasma compared with
the subtherapeutic control group (difference between median changes +0.05 pg/ml (95% CI -0.36 to
+0.47); p = 0.84). If patients with hsCRP values above 8 mg/l at baseline were excluded, differences
between the changes in hsCRP, IL6, IFNgamma and adiponectin after 4 weeks of CPAP were smaller,
and again not statistically different between groups. CONCLUSIONS: 4 weeks of CPAP treatment has
no beneficial effect on blood markers of inflammation and adiponectin in patients with moderate-severe
obstructive sleep apnoea.
doi: 10.1136/thx.2008.097931
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ABSTRACT
Background: Obstructive sleep apnoea syndrome
(OSAS) has been associated with cardiovascular disease
in epidemiological and observational studies. Continuous
positive airway pressure (CPAP) is the treatment of choice
for OSAS, but the impact of this intervention on systemic
inflammation involved in the atherosclerotic process
remains unclear.
Methods: 100 men with moderate–severe OSAS were
randomised to therapeutic (n = 51) or subtherapeutic
(n = 49) CPAP treatment for 4 weeks to investigate the
effects of active treatment on inflammatory markers such
as highly sensitive C reactive protein (hsCRP), interleukin
(IL)6, interferon c (IFNc) and anti-inflammatory adipo-
nectin.
Results: 4 weeks of therapeutic CPAP did not signifi-
cantly change blood levels of hsCRP compared with the
subtherapeutic control group (difference between median
changes 20.24 mg/l (95% CI 20.88 to +0.24);
p = 0.30). Plasma levels of IL6 and IFNc did not change
significantly following therapeutic compared with sub-
therapeutic CPAP (difference between median changes
+0.52 and 20.07 pg/ml (95% CI 20.72 to +1.94 and
20.81 to +0.44); p = 0.45 and p = 0.82, respectively).
Furthermore, 4 weeks of therapeutic CPAP did not
significantly change levels of adiponectin in plasma
compared with the subtherapeutic control group (differ-
ence between median changes +0.05 pg/ml (95% CI
20.36 to +0.47); p = 0.84). If patients with hsCRP values
above 8 mg/l at baseline were excluded, differences
between the changes in hsCRP, IL6, IFNc and adiponectin
after 4 weeks of CPAP were smaller, and again not
statistically different between groups.
Conclusions: 4 weeks of CPAP treatment has no
beneficial effect on blood markers of inflammation and
adiponectin in patients with moderate–severe obstructive
sleep apnoea.
The obstructive sleep apnoea syndrome (OSAS) is
characterised by repetitive apnoeas/hypopnoeas
during sleep, associated with oxygen desaturations
and sleep disruption. It has been estimated that
between 2% and 4% of the adult population in
Western countries suffer from clinically significant
OSAS, and it is becoming more prevalent as the
average population body weight rises.1
Cross sectional and prospective studies have
implicated OSA as an important causal factor in
the development of cardiovascular disease.2 The
mechanisms underlying the association between
OSA and cardiovascular disease are not fully
understood. Multiple causal factors leading to
vessel wall damage and development of athero-
sclerotic plaques have been proposed, including
reflex sympathetic activation and consequent
increases in blood pressure, endothelial dysfunction
and systemic inflammation.3–5
Inflammation plays a central role in the initia-
tion and progress of atherosclerosis and has been
shown to be involved at the onset of adverse
clinical vascular events when activated cells within
an atherosclerotic plaque secrete proteases that
degrade the fibrous cap, leading to rupture of the
plaque and thrombus formation.6 Vascular inflam-
mation involves complex interactions among solu-
ble factors and cells, including proinflammatory
cytokines and proteins (eg, interleukin (IL)6,
interferon c (IFNc), highly sensitive C reactive
protein (hsCRP)) and anti-inflammatory cytokines
and adipokines (eg, IL10, adiponectin).6 7 Increased
levels of inflammatory cytokines and proteins have
also been proposed as useful predictors of future
cardiovascular events.8 9
Several observational studies have investigated
the potential relationship between OSA and
hsCRP, proinflammatory cytokines and adiponec-
tin.10–13 Some of these studies found a positive
correlation between levels of hsCRP, proinflamma-
tory cytokines, adiponectin and the severity of
OSA which was independent of the patient’s
obesity.10–13 However, only a few studies, which
all included a small number of patients, investi-
gated the effects of continuous positive airway
pressure (CPAP) on these pro- and anti-inflamma-
tory markers and have reported conflicting
results.14–19 Furthermore, there are no data from
randomised controlled trials on the effects of CPAP
on proinflammatory cytokines.
To address this uncertainty, we have analysed
stored blood samples from a large scale randomised
controlled trial on CPAP and measures of cardio-
vascular risk in patients with symptomatic OSA20
in order to investigate the effects of CPAP
treatment on hsCRP, proinflammatory cytokines
and adiponectin.
METHODS
Patients
Patients with possible OSA were referred to the
Oxford Sleep Unit, Oxford Centre for Respiratory
Medicine, UK, by general practitioners, ear, nose
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and throat surgeons, or other hospital consultants. Patients
were eligible for the trial if they were males aged between 20
and 75 years who had excessive daytime sleepiness (Epworth
Sleepiness Score >10) and proven OSA with more than 10
oxygen desaturations of.4% per hour (ODI.10/h). All eligible
patients were offered participation in the study, unless they
required urgent CPAP therapy because of respiratory failure,
driving or job issues. The study was approved by the Oxford
research ethics committee (COREC No 96.127) and written
informed consent was obtained from all participants.
Sleep study, CPAP and assessment of sleepiness
OSAS was diagnosed from a 1 night in hospital respiratory
polysomnographic sleep study. Patients’ body movements,
heart rate and pulse transit time changes were recorded as
measures of arousal from sleep. Pulsoximetry, snoring and
increases in the respiratory swing in pulse transit time were
used as markers of breathing pattern and respiratory effort
(Win-Visi monitoring system; Stowood Scientific Instruments,
Oxford, UK) as previously described and validated.21
The results of the sleep study were scored automatically, with
manual review to ensure accuracy of the data. OSAS was
diagnosed from review of all data and severity was quantified as
the number of oxygen desaturations .4% per hour of study
(ODI).
After enrolment, patients were randomly assigned to either
therapeutic or subtherapeutic CPAP, and then underwent
baseline measurements followed by a second sleep study, during
which respiratory polysomnography was repeated and CPAP
was used according to the assigned group. For patients assigned
to therapeutic CPAP, the therapeutic pressure was determined
from overnight use of the Sullivan Autoset-T auto-adjusting
(ResMed, Abingdon, UK) CPAP machine, from which mask
pressure was recorded and synchronised with the sleep study
signals, as previously described and validated.22 The record was
reviewed the next morning, and the optimum pressure to
prevent sleep apnoea, usually the 95th percentile of pressure
overnight, was confirmed by a sleep technician. Patients
assigned to subtherapeutic CPAP used a machine that delivered
,1 cm H2O pressure as previously described,
23 which is
insufficient to hold the pharynx open.
Patients remained blinded as to whether they were receiving
therapeutic or subtherapeutic CPAP, as did the investigators.
The sleep nurse, who randomly assigned patients to the two
Figure 1 Trial profile. CPAP, continuous
positive airway pressure.
Sleep-disordered breathing
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groups, maintained the machines and assisted the patients, was
not involved in outcome assessments.
Subjective sleepiness was assessed using the Epworth
Sleepiness Score which assesses the tendency to fall asleep
during eight typical daytime situations.24 Objective sleepiness
was measured with one sleep resistance challenge (Osler test),
which tests the ability to stay awake in a darkened and sound
isolated room, and was carried out at the same time of day on
the two occasions the patient was studied.25
Cardiovascular risk score
A cardiovascular risk score (Framingham Index) was used to
objectively assess an individual’s 5 year risk of death due to
cardiovascular events.26 The risk score is based on 11 factors
including: age, sex, systolic blood pressure, serum total
cholesterol concentration, height, serum creatinine concentra-
tion, cigarette smoking, diabetes, left ventricular hypertrophy,
history of stroke and myocardial infarction. The risk score is an
integer, with points added for each factor according to its
association with risk. The sum score and corresponding risk of a
fatal cardiovascular event were derived from individual patient
data according to Pocock et al.26
Inflammatory blood markers
Blood was obtained from all patients in the morning between
09:00h and 11:00h at baseline and follow-up. Measurements of
hsCRP, IL6, IFNc and adiponectin were performed from plasma
samples which were stored at 280uC.
The Dade Behring BN method (particle enhanced immuno-
nephelometry, measuring range 0.18–1150 mg/l) was used to
measure hsCRP as previously described and validated.27 The
internal quality control (Dade Behring Apo-Control-Serum
CHD) for measurement of hsCRP has a nominal value of
1.77 mg/l and results are expected to be within the range 1.59–
1.95 mg/l. The mean (SD) value of four quality control runs
was 1.83 (0.06) mg/l.
IL6 and IFNc were measured by ELISA with commercially
available kits (BD OptEIA; BD Biosciences, San Diego,
California, USA). The intra- and interassay coefficients of
variation were 4.1% and 10.9%, respectively, for IL6, and 4.0%
and 9.9 % for IFNc. The lower limit of detection for IL6 and
IFNc with these ELISA kits was 1 pg/ml. Samples with IL6/
IFNc levels ,1 pg/ml were re-evaluated (always in pairs of
baseline/follow-up samples) by commercially available high
sensitivity ELISA kits (BMS213HS and BMS228HS; Bender
MedSystems GmbH, Vienna, Austria). The intra- and interassay
coefficients of variation were 6.9% and 8.0%, respectively, for
IL6, and 6.8% and 7.1% for IFNc. The lower limit of detection
for IL6 was 0.02 pg/ml, and 0.06 pg/ml for IFNc.
Adiponectin was measured by a commercial ELISA kit
(Quantikine Human Adiponectin ELISA; R&D Systems,
Abingdon, UK). The intra- and interassay coefficients of
variation were 4.7% and 6.9%, respectively. The lower limit of
detection was 0.246 ng/ml. All samples were measured in
duplicate and in the same batch.
Follow-up
After baseline assessments, patients used their therapeutic or
subtherapeutic CPAP machine (Sullivan 6; ResMed, Abingdon,
UK) for 4 weeks and then re-attended for repeat measurements
of hsCRP, IL6, IFNc, adiponectin, Epworth Sleepiness Score and
the Osler test. Hour meters on the CPAP machines were
downloaded to calculate mean nightly use. At the end of the
trial, CPAP pressure was re-titrated in every patient to establish
their therapeutic pressure for subsequent long term use.
Table 1 Patient characteristics
Subtherapeutic
CPAP
(n = 51)
Therapeutic
CPAP
(n = 51)
Age (years) 48.7 (10.6) 48.1 (9.5)
Weight (kg) 111.3 (22.0) 115.5 (25.1)
BMI (kg/m2) 34.5 (5.0) 35.8 (7.3)
Neck circumference (cm) 44.6 (3.3) 45.1 (4.0)
Waist/hip circumference ratio 1.01 (0.06) 1.02 (0.06)
Current smokers (%) 17.7 21.6
Ex-smokers (%) 54.9 43.2
Hypertensive (%) 25.5 21.6
Diabetics (%) 2.0 2.0
Cardiovascular risk score (%) 1.75 (1.71) 1.62 (1.82)
Oxygen saturation dips .4% (per hour of
sleep)
42.7 (21.6) 41.9 (25.4)
ESS at baseline 15.2 (4.0) 15.8 (4.0)
Osler at baseline (min) 17.3 (13.1) 18.1 (13.1)
CPAP compliance (h/night) 3.9 (2.5) 4.7 (2.1)
Re-titration CPAP pressure following study
(cm H2O)
10.1 (1.6) 10.0 (1.9)
Values are mean (SD).
Cardiovascular risk score estimates the risk of death (%) in the next 5 years due to a
cardiovascular event.
None of the differences was statistically significant.
BMI, body mass index; CPAP, continuous positive airway pressure; ESS, Epworth
Sleepiness Score.
Table 2 Values for hsCRP, IL6, IFNc and adiponectin before and after treatment
Subtherapeutic CPAP Therapeutic CPAP
Difference in change
(95% CI of difference) p Value*Baseline Follow up Baseline Follow up
hsCRP (mg/l) 2.68 (1.27–4.49) 3.12 (1.33–6.11) 3.05 (1.60–7.12) 2.80 (1.30–5.76) 20.24 (20.88 to +0.24) 0.30
hsCRP{ (mg/l) 2.64 (1.17–3.61) 2.83 (1.02–3.91) 2.36 (1.24–3.61) 2.03 (1.13–4.45) –0.10 (20.64 to +0.30) 0.49
IL6 (pg/ml) 5.13 (2.89–9.38) 5.51 (3.26–7.61) 4.45 (2.13–10.01) 4.82 (2.24–10.96) +0.52 (20.72 to +1.94) 0.45
IL6{ (pg/ml) 4.61 (2.53–7.08) 4.19 (2.81–7.42) 3.47 (2.10–8.93) 3.98 (2.23–9.54) +0.35 (20.73 to +1.60) 0.61
IFNc (pg/ml) 3.37 (0.83–5.87) 4.22 (0.81–6.43) 3.28 (0.49–5.72) 3.37 (0.49–6.67) 20.07 (20.81 to +0.44) 0.82
IFNc{ (pg/ml) 3.40 (0.71–5.99) 4.23 (0.72–7.31) 3.16 (0.52–5.11) 3.70 (0.51–5.92) +0.06 (20.59 to +0.92) 0.74
Adiponectin (mg/ml) 5.80 (3.81–7.35) 5.62 (4.23–7.88) 4.71 (2.74–8.21) 4.60 (2.92–7.86) +0.05 (20.36 to +0.47) 0.84
Values are medians (interquartile range).
95% CI, 95% confidence intervals for difference between median changes.
*p value for comparisons of median changes between groups.
{Subjects with hsCRP values .8 mg/l excluded.
CPAP, continuous positive airway pressure; hsCRP, highly sensitive C reactive protein; IFNc, interferon c; IL, interleukin.
Sleep-disordered breathing
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Data analysis
Data are expressed as mean (SD) for normally distributed data
and medians (interquartile range) for non-normally distributed
data. All statistical analyses were performed with Statistica
V.6.0 (StatSoft, Tulsa, Oklahoma, USA). Differences between
the groups for the outcomes were assessed by independent t
tests if data were normally distributed or by the Mann–
Whitney U test if data were not normally distributed.
Differences in changes between the groups are expressed as
median in the therapeutic, minus median in the subtherapeutic,
groups with the 95% confidence intervals (CI) of the difference.
Data were analysed on an intention to treat basis, with no
change assumed when follow-up hsCRP, IL6, IFNc or adipo-
nectin data were missing. Data were reanalysed as per protocol,
including only those subjects with complete follow-up data to
assess whether this differed from the intention to treat analysis.
For comparison of frequencies, the x2 test of independence was
used. Spearman’s rank test was used for correlation analysis. A p
value ,0.05 was considered to be statistically significant.
RESULTS
Trial profile and patients characteristics
Figure 1 shows the trial profile: 102 patients with a mean age of
48.4 (10.1) years were randomised, 51 to therapeutic and 51 to
subtherapeutic CPAP. The two groups were similar in age, body
mass index, fat distribution, smoking status, frequency of
hypertension (and anti-hypertensive medication), cardiovascular
risk score and severity of sleep apnoea (table 1). Blood samples
from 100 patients were available for analysis at baseline, and from
95 at follow-up. There were no significant correlations between
any of the inflammatory markers and the ODI at baseline.
Data on blood pressure from 52 of the 102 randomised
patients had been used in a previously published study
evaluating the effect of CPAP on ambulatory blood pressure.23
Figure 2 Individual highly sensitive C
reactive protein (CRP) levels at baseline
and follow-up in the subtherapeutic
continuous positive airway pressure
(CPAP) group (A) and the therapeutic
CPAP group (B). Large circles and vertical
bars are medians and interquartile ranges.
Median CRP levels did not change
significantly after 4 weeks of therapeutic
compared with subtherapeutic CPAP.
Subjects with CRP levels .8 mg/l were
excluded.
Figure 3 Individual interleukin 6 (IL6)
levels at baseline and after 4 weeks of
subtherapeutic continuous positive
airway pressure (CPAP) (A) and
therapeutic CPAP (B). Large circles and
vertical bars are medians and interquartile
ranges; for clarity the y axis is
logarithmic. Median IL6 levels did not
change significantly after 4 weeks of
therapeutic compared with
subtherapeutic CPAP. Subjects with
highly sensitive C reactive protein levels
.8 mg/l were excluded.
Sleep-disordered breathing
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Measures of sleepiness
Therapeutic CPAP significantly reduced the Epworth Sleepiness
Score compared with subtherapeutic CPAP (difference between
mean changes 25.3 (95% CI 27.3 to 23.4); p,0.0001), and
improved objective sleepiness measured by the Osler test
(difference between mean changes +7.7 min (95% CI 2.2 to
13.2 min); p = 0.007). Compliance with CPAP did not differ
between the two groups (table 1).
Highly sensitive C reactive protein
hsCRP did not change significantly after 4 weeks of therapeutic
CPAP or subtherapeutic CPAP (table 2). If all patients with
hsCRP values above 8 mg/l were excluded (10 subjects in each
group), which is the threshold for active infection in our
institution, the change in hsCRP with therapeutic compared
with subtherapeutic CPAP was also insignificant (table 2).
Further details on the results are given in table 2, and individual
changes in hsCRP are shown in fig 2.
Cytokines
Interleukin 6
Four weeks of therapeutic CPAP did not change plasma levels of
IL6 significantly compared with subtherapeutic CPAP (table 2).
If patients with hsCRP values above 8 mg/l were excluded, IL6
levels did not significantly change with therapeutic compared
with subtherapeutic CPAP (table 2). As would be expected,
there was a correlation between IL6 and hsCRP at baseline
(r = 0.32 (95% CI 0.13 to 0.49); n = 100, p = 0.001) and at
follow-up (r = 0.46 (95% CI 0.28 to 0.61); p,0.0001).
Figure 4 Individual interferon c (IFNc)
levels at baseline and after 4 weeks of
subtherapeutic continuous positive
airway pressure (CPAP) (A) and
therapeutic CPAP (B). Large circles and
vertical bars are medians and interquartile
ranges; for clarity the y axis is
logarithmic. Median IFNc levels did not
change significantly after 4 weeks of
therapeutic compared with
subtherapeutic CPAP. Subjects with
highly sensitive C reactive protein levels
.8 mg/l were excluded.
Figure 5 Individual adiponectin levels at
baseline and after 4 weeks of
subtherapeutic continuous positive
airway pressure (CPAP) (A) and
therapeutic CPAP (B). Median adiponectin
levels did not change significantly after
4 weeks of therapeutic compared with
subtherapeutic CPAP. Large circles and
vertical bars are medians and interquartile
ranges.
Sleep-disordered breathing
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Interferon c
Plasma levels of IFNc did not change significantly after 4 weeks
of therapeutic compared with subtherapeutic CPAP (table 2). If
patients with hsCRP values above 8 mg/l were excluded,
changes in IFNc levels were still not significant (table 2).
Further details on cytokine results are given in table 2, and
individual changes in IL6 and IFNc are shown in figs 3 and 4,
respectively.
Adiponectin
Four weeks of therapeutic CPAP did not significantly change
plasma levels of adiponectin compared with subtherapeutic
CPAP (table 2). Individual changes in adiponectin are shown in
fig 5.
When data on inflammatory markers were analysed as per
protocol, there was no statistically significant difference in
changes between the therapeutic and subtherapeutic CPAP
groups.
DISCUSSION
We performed a large randomised controlled trial on the effects
of CPAP on blood markers of inflammation, hsCRP, IL6, IFNc
and adiponectin, in patients with moderate to severe OSAS, and
found no improvement in these parameters after 4 weeks of
active CPAP treatment, despite large improvements in both
symptoms and objective sleepiness in the group receiving
therapeutic CPAP. The 95% confidence intervals of the
difference in CRP changes between groups were 20.88 to
+0.24 mg/l. Therefore, we have excluded a significant reduction
in CRP due to CPAP of more than about 1 mg/l. A power
calculation using our data shows that in order to exclude a
significant reduction in CRP as small as 0.5 mg/l, with 90%
confidence at the 5% level, would require 240 subjects in each
arm.
The view that chronic inflammation initiated by monocyte
and lymphocyte adhesion to activated endothelial cells plays a
central role in the pathogenesis of atherosclerosis is now widely
accepted.6 There is also evidence from large epidemiological
studies that levels of inflammatory blood markers, such as
hsCRP and IL6, are independent predictors of future cardiovas-
cular events and mortality in subjects with and without known
cardiovascular disease.9 28 29 Adiponectin, an adipocyte derived
peptide, has been shown to have important effects on the
cardiovascular system, as reduced plasma levels have been
related to insulin resistance, endothelial dysfunction and
coronary heart disease.30 31
In the present study, we found that 4 weeks of CPAP did not
lower plasma levels of hsCRP in patients with moderate to
severe OSA. This finding confirms the negative results we
found in a recently published smaller study on the effects of
CPAP on hsCRP in patients with newly diagnosed type 2
diabetes and OSA.17 To our knowledge, the effects of CPAP on
hsCRP have only been investigated in one other randomised
controlled trial. Drager and colleagues32 randomly assigned 24
patients with severe OSA to either CPAP or no treatment, and
found a significant decrease in hsCRP after 4 months of CPAP
therapy. A possible explanation for the conflicting findings
could be that all patients included in the study by Drager and
colleagues32 were free of any comorbidities, whereas we
included typical OSA patients, some of which had arterial
hypertension, diabetes and an increased cardiovascular risk
score (table 1). In fact, we found that the chance of a fatal
cardiovascular event in the next 5 years was 1.7% in our
population compared with the risk of 0.4% for healthy men of
similar age26 (ie, a fourfold increase).
The present study is the first randomised controlled trial
which has investigated the effects of CPAP on proinflammatory
cytokines such as IL6 and IFNc. We found that 4 weeks of
CPAP therapy had no significant effect on plasma levels of these
cytokines. Furthermore, levels of proinflammatory IL6 and
hsCRP were correlated at baseline and at follow-up (r = 0.32
and r = 0.46, respectively, p,0.001), which strengthens our
negative findings. The results of our trial are in concordance
with the uncontrolled study of Phillips and colleagues16 who
found no change in IL6 levels after short term withdrawal
(7 nights) from CPAP. However, Yokoe and colleagues19 found
significantly decreased levels of both CRP and IL6 after 4 weeks
of CPAP in an uncontrolled study, studying only 17 patients
with moderate–severe OSA.
There has been growing interest in the adipocyte derived
anti-inflammatory protein adiponectin and its relationship
with OSA. There are conflicting reports from observational
studies regarding the association of OSA with blood levels of
adiponectin, and the results from small uncontrolled studies
on the effects of CPAP on adiponectin are not conclusive.33 34
We recently reported that 3 months of CPAP therapy did not
increase plasma levels of adiponectin or reduce insulin
resistance in patients with type 2 diabetes and OSA.17 In
the present study, we found that 4 weeks of therapeutic
CPAP did not significantly change plasma levels of adiponec-
tin compared with subtherapeutic CPAP. The reasons for the
lack of a change in adiponectin are not clear but may be due
to an overwhelming impact of obesity on adiponectin
secretion as body mass index was relatively high (35.2 kg/
m2) in our study population.
It could be argued that the lack of effect of CPAP therapy
on markers of systemic inflammation was caused by the
relatively short duration of treatment (4 weeks), although
studies on statin therapy have shown a significant reduction
of circulatory proinflammatory cytokines in under 7 days
following the initiation of therapy.35 However, we cannot
exclude the possibility that CPAP treatment over several
months might gradually reduce systemic inflammation, and
this should be addressed in future longer term randomised
controlled trials.
Baseline measurements in our study were performed imme-
diately after randomisation rather than before but, since both
the investigators and patients remained blinded to the allocated
group, this is unlikely to have introduced a bias.
In conclusion, this double blind randomised controlled trial
has shown no improvement in inflammation measured by pro-
and anti-inflammatory blood markers in patients with
moderate to severe OSA following CPAP treatment, despite
symptomatic improvement, as evidenced by large reductions in
both subjective and objective sleepiness. The reasons for this
are not clear but may be due to the overpowering effects of
other cardiovascular risk factors on systemic inflammation.
Therefore, we have found no evidence that CPAP produces a
cardiovascular benefit through reduction of systemic inflam-
mation in a typical cohort of patients with moderate–severe
OSA.
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